The following issues have been halted by CIRO: Company: Intact Financial Corporation TSX Symbol: IFC.PR.M All Issues: No Reason: Pending Closing Halt Time (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and […]
Dental Implants Market Growth Outlook: CAGR of 7.3 % and Value Reaching USD 9.07 Billion by 2032 | says Coherent Market Insights GlobeNewswire November 12, 2025 Burlingame, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) — The Global Dental Implants Market is estimated to be valued at USD 5.54 Bn in 2025 and is expected to reach
WALLINGFORD, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) — X9, Inc. today announced positive results from its first-in-human clinical feasibility study evaluating the X9 Ultrasound System with Power-Assisted Needle Insertion, the company's innovative handheld device for ultrasound-guided, power-assisted needle insertion in arteriovenous fistula (AVF) cannulation for hemodialysis patients. The clinical study was conducted at the Territorial
Robbins LLPinforms stockholders that a class action was filed on behalf of all investors who purchased Firefly Aerospace Inc. (NASDAQ: FLY) (a) common stock pursuant to the Offering Documents issued in connection with the Company's initial public offering (“IPO”) on August 7, 2025, or (b) securities between August 7, 2025 and September 29, 2025. Firefly
New national insights data from Motive Medical Intelligence show persistent overuse of unnecessary endoscopy for heartburn, with sharp geographic disparities. Despite years of professional guidance discouraging doctors from performing routineendoscopy for heartburn-known medically as gastroesophageal reflux disease, or GERD-new national insights data from Motive Medical Intelligence (Motive) show that millions of Americans with simple heartburn
X9, Inc. Announces Successful Completion of First-in-Human Feasibility Study for Ultrasound-Guided, Power-Assisted Needle Insertion Device in Hemodialysis Cannulation GlobeNewswire November 12, 2025 WALLINGFORD, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) — X9, Inc. today announced positive results from its first-in-human clinical feasibility study evaluating the X9 Ultrasound System with Power-Assisted Needle Insertion, the company's innovative handheld
Collaboration unites Equum’s 24/7 enterprise telehealth operations with Dr. Lahr’s clinical informatics expertise to help hospitals build alwaysâ?’on hybrid care NEW YORK, NY / ACCESS Newswire / November 12, 2025 / Equum Medical, a leader in integrated acuteâ?’care telehealth and virtual clinical staffing, today announced a strategic partnership with Vital Thread Advisory, the strategic insights
(NYSE MKT:OPTT), MONROE TOWNSHIP, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (NYSE American: OPTT), a leader in intelligent maritime systems and ocean energy solutions, today announced a partnership with Mythos AI to integrate advanced AI-driven autonomy software across OPT's fleet of WAM-V(R) Autonomous Surface Vehicles (ASVs) and PowerBuoy(R) platforms. This collaboration
(NASDAQ:NUWE), MINNEAPOLIS, MN, Nov. 12, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today reported financial results for the third quarter ended September 30, 2025 and provided a business update on recent milestones
Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities, including a Type C meeting with the FDA, to potentially accelerate (Z)-endoxifen in breast cancer risk reduction Appointed key leadership to drive (Z)-endoxifen development and evolve pathway to commercialization Atossa Therapeutics, Inc.